U.S. markets close in 2 hours 50 minutes

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
44.50+0.50 (+1.14%)
At close: 5:06PM BST
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

Currency in GBP. All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
Total Revenue
9,208
719
11,881
637
Cost of Revenue
1,185
485
311
155
Gross Profit
8,023
234
11,570
482
Operating Expense
9,937
9,269
16,738
21,433
Operating Income
-1,914
-9,035
-5,168
-20,951
Net Non Operating Interest Income Expense
324
16
-15
-2
Pretax Income
-1,636
-9,066
-5,153
-20,994
Tax Provision
-142
-266
-3,359
-1,406
Net Income Common Stockholders
-1,494
-8,800
-1,794
-19,588
Diluted NI Available to Com Stockholders
-1,494
-8,800
-1,794
-19,588
Basic EPS
-
-0.08
-0.02
-0.17
Diluted EPS
-
-0.08
-0.02
-0.17
Basic Average Shares
-
116,987
116,426
112,358
Diluted Average Shares
-
116,987
116,426
112,358
Total Operating Income as Reported
-1,913
-9,035
-5,168
-20,951
Rent Expense Supplemental
-
179
-
-
Total Expenses
11,122
9,754
17,049
21,588
Net Income from Continuing & Discontinued Operation
-1,494
-8,800
-1,794
-19,588
Normalized Income
-1,494
-8,800
-1,794
-19,588
Interest Income
321
18
20
15
Interest Expense
-4
1
22
17
Net Interest Income
324
16
-15
-2
EBIT
-1,640
-9,065
-5,131
-20,951
EBITDA
716
-
-
-
Reconciled Cost of Revenue
1,185
485
311
155
Reconciled Depreciation
2,356
2,621
2,354
2,437
Net Income from Continuing Operation Net Minority Interest
-1,494
-8,800
-1,794
-19,588
Normalized EBITDA
716
-6,444
-2,777
-18,514
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0